Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data

Dyne Therapeutics, Inc.

2024-Q1 EPS reported -$0.81

Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.
Cash, equivalents and marketable securities $453.5M; expects funding through 2025.
R&D expenses $44.5M (up 19% YoY); G&A expenses $24.6M (up 211% YoY) largely due to new CEO.
John Cox appointed CEO and President in March 2024.
Phase 1/2 ACHIEVE (DM1) and DELIVER (DMD) trials progressing; additional data expected H2 2024 with registrational cohorts by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dyne Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $65.6 million, or $0.81 per basic and diluted share, EPS $0.81 per basic and diluted share.

Period: the quarter ended March 31, 2024
Net income: $65.6 million, or $0.81 per basic and diluted share
EPS: $0.81 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.